Treatment with combination chemotherapy has not resulted in that PB stem cell harvests are often contaminated with myelong-term remissions in multiple myeloma (MM) despite loma tumor cells. 5,[8][9][10] [11] In fact, one study indicated that the advances in drug discovery and protocol improvement over the presence of contaminating tumor cells in the autograft was 
Introduction chemotherapy, MRD can still be detected, even when patients achieve clinical complete remission (CR). 17 In contrast to the Multiple myeloma (MM) is an incurable B cell malignancy significant reduction in BM tumor load post-chemotherapy, in characterized by the clonal expansion of plasma cells within a limited analysis we observed very little tumor reduction the bone marrow (BM) as determined by clonal Ig heavy and within the PB. 4 Furthermore, we found that PB involvement light chain genes in the BM and by the production of a clonal was independent of disease stage and of BM tumor involveimmunoglobulin (Ig) M-protein in the serum. Although the disment. 4 ,21 Previous analysis of BM and PB post-transplant in ease is responsive to combinations of chemotherapeutic MM using an Ig gene fingerprinting technique has shown that agents and steroids, relapse is inevitable, with a median surpatients achieving CR lack detectable clonal rearrangevival of 36 months. 1 In an attempt to improve outcomes, conments. 22 Caution is necessary regarding this approach for ventional chemotherapy followed by allogeneic or autologous identification of MRD in these patients because Ig gene BM transplants have been used, however, both relapse and fingerprinting is far less sensitive than ASO-PCR. 23 serious toxicity are frequent, yielding improved but still quite In an attempt to monitor MRD, predict early relapse, and limited survival. [1] [2] [3] One potential problem with the use of BMdetermine the involvement of the PB in the disease process, derived stem cells is contamination of the autograft with myewe analyzed serial samples of BM and PB from six patients loma plasma cells.
prior to and after autologous PBSCT. We found that while 3-It is becoming increasingly clear from our own data that the to 4-log reductions were common in BM tumor burden postmajority of patients with MM contain circulating tumor cells, transplant, tumor levels in the PB changed only slightly. Morealbeit at significantly lower levels than observed in the BM. 4, 5 over, upon sequential analysis, the PB tumor signal remained The use of stem cells from the peripheral blood (PB) for transplantation is becoming widespread due to the enhanced quite stable, was not predictive of BM tumor involvement, and myeloid engraftment and to lower level contamination of the did not correlate to events occurring in the BM, ie it was not autograft.
6,7 Nonetheless, several investigators have reported predictive of relapse. These data further illustrate the autonomy of the tumor in the PB of patients with MM, and further suggest that it may be a disease compartment that is refractory to chemotherapy.
Materials and methods

Consensus PCR of rearranged Ig genes from myeloma BM samples Patient population
Initial patient BM DNA was subjected to VFr1c/JH consensus or JH-specific PCR. The 50 l reaction contained the followSix patients were analyzed in this study (Table 1) . Patients were given two cycles of priming chemotherapy (melphalan) ing: 1 g of DNA, 1× PCR buffer (1.2 mM MgCl 2 , 20 mM Tris (pH 8.4), and 50 mM KCl), 200 M dNTP, 20 pmol of each plus hematopoietic growth factor (G-CSF, GM-CSF) treatment for tumor depletion and PB stem cell mobilization. Patients primer, 2.5 units of Taq polymerase (Van Ness Lab, HB1), and 50 l of mineral oil. The sequences of VFr1c and JH consenunderwent autologous PBSCT following high-dose cyclophosphamide and total body irradiation, using their cryopreserved sus have been previously given. 17, 24 The sequence of the JHspecific oligos are: J145 (5Ј-GACTCACCTGAGGAGACG PBSC. Following the priming chemotherapy samples were planned for collection and analysis as follows: 1 week pre-GTG-3Ј), and J3 (5Ј-TGAAGAGACGGTGACCATTGTC-3Ј). The cycling conditions were, an initial denaturation of 5 min transplant, and 1 month, 3 months, 6 months, 9 months, 1 year and 2 years post-transplant. One patient (T49) relapsed at 94°C, followed by 40 cycles of denaturation at 92°C for 15 s, annealing at 60°C for 15 s and extension at 74°C for at 6 months post-transplant, and two other patients (T172 and T210) only had samples to 1 year available for analysis. All 25 s. PCR products were separated on 7% polyacrylamide gels as previously described. 17 Along with each patient sample a patients were treated in the BMT outpatient clinic at the University of Minnesota Hospital. Patients received prophylactic normal marrow sample was run as a control. In the absence of a clonally expanded population we did not obtain a single antimicrobial therapy to reduce infection, growth factors to accelerate myeloid recovery, as well as blood product and PCR product, but rather a nonspecific smear. additional supportive care measures as previously reported for autograft recipients at our institution. After stable multilineage engraftment and platelet recovery to Ͼ80 × 10 3 /l patients Sequencing of amplified products initiated maintenance therapy with ␣-interferon. Treatment and sample collection was done under informed consent PCR amplified products were isolated as previously described. 25 The sample was desalted on Ultra-free-MC using procedures approved by the Institutional Review Board: Human Subjects Committee of the University of Minnesota. 100 000 NMWL filters (Millipore, Bedford, MA, USA). DNA sequencing was performed using the Sequitherm cycle sequencing kit (Epicentre Technologies, Madison, WI, USA) as per supplier's protocol, but with the following modification.
BM and PB sample preparation and DNA isolation
Sequencing reactions containing the sequencing buffer, endlabeled primer, template, and polymerase were subjected to The initial BM sample used to generate the Ig consensus PCR product (see below) is the first sample obtained prior to initial a 5 min denaturation step at 95°C, followed by a snap-cool annealing of the primer to the template by placing in an ice protocol therapy, although all patients were previously treated before transplant study enrollment. Heparinized or EDTAbath 10 min prior to distribution into termination mixes. The sequencing reactions were separated on an 8% denaturing treated patient BM and PB samples were obtained and mononuclear cells (MNC) were isolated on Ficoll-Hypaque (Sigma, gel, and exposed to X-ray film from 2 h to overnight. St Louis, MO, USA). DNA was prepared from the MNC of patients by salt-out extraction. Briefly, the cell pellet was resuspended in 1 ml of TE (10 mM Tris pH 8.0, and 1 mM Quantitation of residual disease in BM and PB samples post-transplant by ASO-PCR EDTA) and then 2 ml of TNES (10 mM Tris pH 8.0, 1 mM EDTA, 50 mM NaCl and 0.5% SDS) was added to lyse the cells. The cells were incubated at 55°C for 1 h to ensure comAllele-specific-oligonucleotides were generated using a PCRMate oligo synthesizer (ABI, Foster City, CA, USA) to the most plete cell membrane solubilization. Next, 1 ml of 5 M NH 4 Ac was added, vortexed for 15 s, and placed on ice for 30 min to specific portion of the CDR3 region based on BLAST (NCBI) sequence search comparisons. ASO-PCR was essentially perfacilitate the precipitation of the proteins. Precipitated proteins were pelleted by centrifugation at 3000 r.p.m. for 15 min. The formed as previously described. 4, 17, 21 In brief, patient marrow DNA dilution curves were generated by serially diluting the supernatant was saved and the DNA was precipitated by the addition of an equal volume of isopropanol. The DNA precipipatient DNA into sterile ddH 2 O in 10-fold decrements. Then an appropriate amount of patient-diluted marrow DNA was tate was washed 2× in 70% ethanol, air dried, and resuspended in 100-500 l TE depending on the yield of DNA.
mixed with normal marrow DNA to yield a target concentration of 1 g DNA/50 l reaction. Along with the diluted The PCR product was then separated on an 8% polyacrylamide gel and exposed to a phosphorimage screen for 1 to 2 h (Molecular Dynamics, Sunnyvale, CA, USA). The exposed shown in Figure 1 . Based on published sequences, 26 ,27 the DH gene segment used and the number of nucleotides deleted phosphorimage surface was analyzed using a Molecular Dynamics Phosphorimager (Molecular Dynamics) and signal from the JH gene segment were determined. These sequences highlight the individuality of the CDR3 region, and demonintensities from the radiolabeled PCR products were determined using the IP Lab Gel software (Signal Analytics Corporstrate how ASOs designed to this region could be used for patient-specific detection. The ASO used for patient-specific ation, Vienna, VA, USA). Standard curves generated from serial dilutions showed correlation coefficients Ͼ0.95; Scheffe's tumor detection is underlined. The ASO-PCR method used was as previously described, 4 and provided an estimate of 95% confidence intervals were computed as previously described 4 and ranged within 0.5 log of the experimentally tumor DNA content which was then converted to an estimate of tumor cell content. determined value. This approach has been demonstrated to be highly specific for detection of cells clonally related to the plasma cell tumor. 4, 17 Another level of specificity generated by the ASO-PCR amplification is reflected in the size of the Quantitative ASO-PCR analysis of BM MRD after ASO-PCR product from the first BM and PBL samples (ie ident-PBSCT ical in size to the product obtained from the patient's original bone marrow sample). In all cases negative controls included
The initial BM tumor burden used to calculate the amount of ASO-PCR of normal BM, as well as cross-checks on unrelated MRD in the BM and PB samples pre-and post-transplant (seen tumor samples.
in Table 2 ) was obtained from the Bone Marrow Transplant Clinic, University of Minnesota. Initial BM samples ranged from a high of 80% (T51) to a low of 1% (T210). The first Results sample after the initial BM represents a post-priming, 1 week pre-transplant sample. As can be seen in Figure 2 , there was
Consensus amplification and sequencing of the a 1-to 2.5-log reduction in BM tumor burden in this sample rearranged Ig heavy chain from MM patients initial following the initial two cycles of priming chemotherapy and BM stem cell harvest. At 1 month, following high-dose chemotherapy, total body irradiation and PBSCT, residual tumor was detected in the BM from all patients, suggesting incomplete VH and JH primers were used to amplify the clonal rearrangement from the initial BM sample of six patients undergoing tumor depletion by the chemo-radiotherapy conditioning or repopulation by reinfused PBSC tumor cells. In the subsequent analogous PBSCT. In each case, a single amplified product was observed following PCR amplification (data not shown).
post-transplant BM samples, four of the six patients showed further reductions in BM tumor burden (Figure 2 , patients: The products were sequenced as described above and the CDR3 region, along with the VH and JH boundaries, are T47, T120, T172, T210), approaching 3-to 3.5-logs reduction, with some variation over time. The increase observed in patient T47 at 1 year post-transplant coincided with a clinical diagnosis of progressive BM myeloma. After additional therapy, clinical and PCR measures of the BM tumor burden showed improvement at the 2 year timepoint (Figure 2, T47) . Patient T51 showed a greater than 2-log decrease in tumor by 3 months post-transplant. However, by ASO-PCR, the 1 year sample showed an estimated tumor burden of 14% which remained stable to 2 years post-transplant. Patient T49, after an initial tumor reduction Ͼ2-logs at 1 month, relapsed by clinical and PCR measures of the BM at the 3 month evaluation. These data indicate that the BM tumor burden can be reduced substantially by a combination of chemotherapy, TBI and PBSCT. However, complete molecular remission, as measured by the absence of an ASO-PCR signal, was not observed in any of these six patients.
Quantitative ASO-PCR analysis of circulating tumor ing the course of disease. In a previous limited analysis, we found that tumor reduction in the BM is affected to a greater extent by chemotherapy than is the PB. 4 We therefore analyzed sequential PB samples from six patients to extend these studies, and determine the affect of chemotherapy and PBSCT on the level of circulating tumor cells in the PB over time. Tumor contamination of the initial PB sample from these six patients ranged from 0.009-3% of the total mononuclear as determined by ASO-PCR (Figure 2) . Interestingly, sequential analysis of the PB samples showed that in contrast to the BM, there is little variation in the PB tumor content and very little tumor reduction post-transplant. Moreover, in the majority of patients, the PB tumor burden remained quite constant posttransplant, and was not affected by either the priming chemotherapy or the transplant conditioning.
Two patients demonstrated nearly 1-log decreases in PB tumor at 1 month post-transplant (T49 and T172). One patient had sustained tumor depletion in PB to 1 year, while in the other, the PB tumor content, although increasing slightly over time, remained below the initial PB level. Discordance in PB and BM tumor content over time was common. Notably for three patients increases of nearly 2-logs in the BM tumor burden were not associated with concomitant increases in the PB tumor content (T47, T51, T120). In fact, in patients T47 and T51 the level of PB involvement remained unchanged to 1 year, despite a nearly 2-log increase in BM tumor. In patient T120, no PB tumor was detected, despite a 2-log increase in BM tumor at 22 months post-transplant. positive selection techniques such as CD34 affinity devices can further deplete the harvest of tumor cells by as much as TBI, should allow one to monitor the extent to which each compartment is contaminated both before and after transplan-4-logs. 28 However, relapse remains common even after PBSCT, 3, 12 suggesting that incomplete eradication of the tation. Although CD34 selection of the autograft can enrich stem cells and likely deplete tumor, this approach has not tumor within the patient is the primary contributor to relapse. It is clear from our data, that the majority of patients with MM clearly increased remission rates after transplant. 28 In another report it was found that purification of the more primitive have tumor involvement in the PB.
Discussion
4,21 Therefore, depletion of tumor from both the patient BM and the PB graft are important hematopoietic precursor, CD34 + , Lin − , Thy1 + cells, from the PBSC harvests significantly decreased myeloma tumor confor successful transplant.
In this study, we used ASO-PCR to quantitate residual tumor tamination. 18 However, the efficacy of using such purified stem cell populations for autotransplant in MM has not yet pre-and post-transplant in the BM and PB of six myeloma patients. We have found that the BM tumor burden may been demonstrated. Together, these data support the contention that current clinical stem cell harvests are ineffective in decrease in some patients by as much as 4-logs after transplant. However, after pre-transplant priming and at 1 month tumor depletion and are a major contributor to post-transplant relapse. post-transplant all patients had detectable clonal DNA in the BM. Similarly, PB tumor cells were detected in the majority Further improvements in the control of MM through autotransplant therapies must address both a cleaner graft and of patients both before and 1 month after transplantation. Significantly, we found that the PB tumor content remains quite more effective anti-tumor measures. Longitudinal studies that utilize cellular and molecular analyses of BM and PB can betstable over the course of disease post-transplant, and does not reflect the tumor burden in the BM. Moreover, the stable perter assess the value of pre-treatment and post-transplantation therapies. The relatively stable tumor content of the PB as sistence of PB tumor involvement was not predictive of either marrow involvement or later relapse.
reported here would suggest this compartment may be an important contributor to perpetuating the disease. Previous studies using immunofluorescence microscopy or flow cytometry have shown that clonal circulating plasma cells or mature B cells are present in the majority of newly Acknowledgements diagnosed patients with myeloma. 8, 29 Decreases in the number of clonal plasma cells were found in patients that This work was supported by Public Service Grant PO1 responded to chemotherapy, whereas relapsing or refractory CA65493 from the National Cancer Institute of the National patients showed increases in circulating clonal plasma Institutes of Health. cells. 8, 29 In contrast, we found only slight variation in the PB over time in six patients analyzed sequentially. For the most part, the PB remained a very stable compartment, showing References little or no change either after priming chemotherapy or after transplantation. Importantly, for each individual patient we cells in the autograft is predictive of an early relapse. 11 The
